Indication intelligence, analysis and sector perception

RegMed’s close: low volume, fear, migrating momentum and obfuscated indicators

October 19, 2015 6:34pm

The who, why, when, where and what of a neutral close of 43 covered companies.

Monday's daily trading report: 8 hits and 2 miss. Subscription required: http://www.regmedinvestors.com/user/register

Make RegMed Investors your daily destination. We’ve gathered and sifted through news and share pricing data you need in one convenient spot.

The stock indexes closed at session highs Monday as they stretched a nearly three-week advance. The NASDAQ climbed 0.4%, the Dow added 0.1%, and the S&P 500 edged up a fraction. Indexes rallied in the closing minutes after some seesaw trading. Volume was lower across the board,

The NASDAQ closed UP +18.78 or +0.38% to 4,905.47 and the DOW closed UP +14.57 or +0.08% to 17,230.54.

Henry’omics:

The stem, cell, gene therapy and regenerative medicine (SCGT&RM) sector opened to the downside quickly moving to the upside by the first hour of the session (10:30 pm) slipping negative at the mid-day to close to neutral of the 43 companies covered as the indexes and ETFs ride the carousel:

The iShares Biotechnology Stocks ETF (IBB) closed UP on Monday +1.62 or +0.52% after Friday’s decline of -0.44 or -0.14%;

The NASDAQ Biotechnology index (NBI) closed UP +18.62 or +0.57% following Friday’s decline of -3.36 or -0.10%;

The Russell 2000 (IWM) closed UP +0.22 or +0.19% following Friday’s decline of -0.15 or -0.13%;

The SPDR SD&P Biotech ETF (XBI) closed UP +0.51 or +0.77% following Friday’s decline of -0.26 or $0.39%

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector:

The roving mode and tone of “our’ universe stumbling sets the tone for the week, so far telling us which way is up, followed by down and moving to a neutral share pricing suppression.

Investors and even traders are having second thoughts about any strength!

The issue is investors are renting through ETFs as traders extend the volatility due to the lack of actionable <individual> company news as the sector plays up and down board games.

The Nasdaq Composite rose as the iShares Biotechnology ETF (IBB) gained about 1.62%.

The issue: the SCGT & RM equities traded in a narrow range on a carousel with low volume, Monday!

SCGT & RM equities opened negative with an Advance/Decline line (A/DL) of 17/23 and 3 flats spiking lower to a positive A/DL at the mid-day of 31/9 and 3 flats and closed with a neutral A/DL of 20/20 and 3 flats.

My fear gauge of fear - the CBOE Volatility Index (VIX) traded near 15 following Friday’s near 16 after Thursday near 16 following Wednesday’s below 18 following Tuesday’s above 17.5 after Monday’s above 15 – watch the shift over the next days!

The sector’s venue hasn't changed: “Veniremus, emimus, vendidit” – the new mantra, we came, we bought, we sold!

Dosing the sector – 43 Patients:

Open: NEGATIVE with 23 decliners, 17 advancers and 3 flats;

1^st hour (10:30 pm): POSITIVE with 12 decliners, 28 advancers and 3 flats;

Mid-day (1 pm): NEGATIVE with 28 decliners, 13 advancers and 2 flats;

3 pm: NEGATIVE with 23 decliners, 17 advancers and 3 flats;

Closing bell: NEUTRAL with 20 decliners, 20 advancers and 3 flats

Monday’s trading indications: 8 hit/ 2 miss:

Applied Genetic Technologies (AGTC) closed DOWN - miss;
bluebird bio (BLUE) closed DOWN – miss;
Capricor (CAPR) closed DOWN - hit;
Caladrius (CLBS) closed DOWN – hit;
Juno therapeutics (JUNO) closed DOWN – hit;
Intrexon (XON closed UP - hit;
MiMedx (MDXG) closed UP – hit;
Osiris (OSIR) closed UP - hit;
Spark Therapeutics (ONCE) closed DOWN – hit;
Verastem (VSTM) closed DOWN – miss;

Who was UP – highest 5:

Kite Pharma (KITE) closed up +$2.64 to $65.71;
Spark Therapeutics (ONCE) +$0.78 to $53.59;
Cellectis ADR (CLLS) +$0.76 to $26.59;
Aduro biotech (ADRO) +$0.73 to $23.63;
Intrexon (XON) closed up +$0.67 to $33.74;

Who was down?

Bluebird bio (BLUE) closed -$3.74 to $81.83;
Regenxbio (RGNX) -$1.45 to $17.20;
Juno Therapeutics (JUNO) -$0.92 to $49.29;
uniQure (QURE) -$0.41 to $18.86;
Fate Therapeutics (FATE) closed down -$0.33 to $4.35

Who is flat?

Athersys (ATHX) at $1.12;
Pluristem (PSTI) at $1.77;
VistaGen (VSTA) at $8.00

All investments are subject to risks. Investors should consider investment objectives. The information included above as well as individual companies and/or securities mentioned should only construed as an indication from any RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.